How Disease Charities Fund Research vs. NIH

Disease-focused charities — the American Heart Association, American Cancer Society, Michael J. Fox Foundation, and dozens of similar patient-advocacy organizations — collectively fund billions of dollars in biomedical research every year. For a principal investigator or research administrator used to NIH mechanisms, this funding looks superficially similar (fellowships, career awards, project grants, peer review) but runs on a genuinely different model: smaller awards, shorter periods, sharply capped indirect-cost recovery, and — in many cases — a review process that includes non-scientist patient advocates alongside scientific peer reviewers. This guide uses the American Heart Association (AHA) as the anchor example, because it is one of the largest and most established disease-charity funders, and maps the broader category against the NIH mechanisms a US-based researcher already knows.

Last verified: August 16, 2026. Figures below are drawn from each funder’s own published policies where cited directly; several charities do not publish a single, consistently stated indirect-cost figure across all award types, and those cells are marked accordingly rather than estimated.

How Disease-Charity Funding Differs From NIH Funding

Five structural differences consistently catch investigators and research offices off guard when they move from a federal award to a disease-charity award:

Smaller awards, shorter periods. Where an NIH R01-equivalent project might run $250,000-$500,000/year in direct costs for up to five years, most disease-charity project and pilot grants top out in the tens of thousands to low hundreds of thousands of dollars per year, typically for one to three years.
Facilities & Administrative (F&A) cost caps well below a federally negotiated rate. A research-intensive university’s federally negotiated indirect cost rate agreement (NICRA) commonly runs 50-70%+ of modified total direct costs. Disease charities typically cap indirect cost recovery at a flat 0-15% of direct costs — a fixed institutional allowance written into the award terms, not a negotiated rate.
Lay summaries are usually required, not optional. Most disease charities require a plain-language project summary, written for a donor/patient audience, as a mandatory application component — distinct from an NIH abstract, which assumes a scientifically literate reader.
Review panels often include patient/lay reviewers alongside scientists. Many disease charities build formal patient-advocate or “consumer” review into their peer-review process, weighting relevance-to-patients alongside scientific merit. NIH study sections do not do this as a matter of course.
Findings-sharing with the patient community is frequently an explicit award condition. Several charities require or strongly encourage grantees to report back to the funder’s patient/advocate community in accessible language, separate from the standard scientific progress report.

None of this makes disease-charity funding lesser or lower-stakes than federal funding — for many disease areas, charity funding is what keeps early-stage and high-risk work alive between NIH cycles. It does mean the application, budgeting, and reporting mechanics are genuinely different, and a proposal or budget built by copying an NIH template usually needs real rework, not just a font change.

The Award Ladder: Mapping Charity Awards to NIH F/K/R Mechanisms

Almost every disease-focused charity that funds individual investigators uses some version of the same three-rung ladder. The rungs map loosely — not exactly — onto the NIH progression a US researcher already understands:

NIH mechanism a researcher already knows	What it does at NIH	Disease-charity equivalent
F31 (predoctoral NRSA)	Stipend/support for a PhD candidate’s dissertation research	Predoctoral fellowship — most large disease charities offer a 1-2 year analogue, usually with a smaller stipend and no separate institutional allowance
F32 (postdoctoral NRSA)	Stipend/support for a postdoc’s independent research training	Postdoctoral fellowship — typically 2-3 years, mentor required, disease-focus-specific eligibility
K01/K08/K23 (mentored career development)	Protected research time for a junior faculty investigator, mentored, non-renewable	Career Development Award (see the AHA CDA example below) — structurally similar: mentoring team, percent-effort commitment, non-renewable, but shorter and smaller than an NIH K award
R21 / R03 (exploratory/small grant)	1-2 year, limited-budget award for an early-stage or high-risk idea, minimal preliminary data required	Innovation, pilot, seed, or “new investigator” grant — the most common single award type disease charities offer; usually 1-2 years, modest budget
R01 (independent investigator project grant)	Multi-year, larger-budget independent research project	Rare in pure form. A handful of the largest, best-endowed charities fund multi-year “program” or “research grant” awards in this range, but for most disease charities their single largest individual-investigator mechanism is still smaller and shorter than an R01.

The practical implication for a research office: a junior investigator’s funding portfolio increasingly includes several of these charity awards stacked together (a postdoctoral fellowship, then a career development award, then two or three pilot/innovation grants) rather than a single large grant, because no individual disease-charity mechanism replaces an R01 in scale. Budget and effort-reporting systems built around “one big federal award per PI” need to accommodate this stacking pattern.

American Heart Association: The Anchor Example

AHA is one of the largest disease-focused charity funders of cardiovascular and stroke research in the US, and its Career Development Award (CDA) is a well-documented, representative example of how the career-development rung of the ladder actually works in practice. Per AHA’s own published 2027-cycle policy: the CDA is a non-renewable, three-year award of up to $231,000 total ($77,000/year, including a 10% institutional indirect cost allowance), requiring a minimum 10% effort commitment, a formal mentoring team (a primary mentor plus at least one secondary mentor outside the applicant’s home department), a 3-page Career Development Plan, and an 8-page Research Plan. Eligibility is capped at six years post-first faculty appointment. See the dedicated AHA Career Development Award guide for the full eligibility, timeline, and application detail — that page, not this one, is the authoritative source for CDA specifics.

AHA also funds predoctoral and postdoctoral fellowships and innovation-project-style grants across the cardiovascular and stroke research portfolio; those mechanisms follow the same general ladder pattern above, but AHA’s own site should be checked directly for the current cycle’s dollar figures and F&A terms for any mechanism other than the CDA, since award terms are revised cycle to cycle and were not independently re-verified for every AHA program in this session.

Patient-Advocate and Lay Review: What It Is, and Why Proposals Fail It

A meaningful share of disease-focused charities build non-scientist reviewers — patients, survivors, caregivers, sometimes described as “consumer” or “advocate” reviewers — into their peer-review process, either on a joint panel with scientists or as a separate scoring component that factors into the final funding decision. Susan G. Komen’s long-running Advocates in Science program, which trains breast cancer survivors and previvors to serve as reviewers on Komen’s own grant panels, is one of the more visible, long-established examples of this model in the disease-charity space.

Proposals that sail through scientific peer review still fail lay/advocate review for predictable, avoidable reasons:

The lay summary is written like an abstract, not a summary. Jargon, unexplained abbreviations, and passive-voice hedging read as evasive to a non-scientist reviewer, even when the underlying science is strong.
Patient relevance is asserted, not shown. “This research will improve outcomes for patients” is a claim; a lay reviewer wants one or two concrete sentences on which patients, what specific outcome, and roughly when — not eventually-someday framing.
The proposal never answers “why does this matter to someone living with this disease right now.” Basic-science and mechanistic proposals are frequently strong candidates for charity funding, but the lay summary needs to bridge from mechanism to patient impact explicitly — a lay reviewer should not have to infer it.
Budget and timeline claims are inconsistent with the plain-language narrative. A lay summary that promises a near-term clinical benefit paired with a purely exploratory, multi-year discovery-phase research plan reads as a mismatch to a reviewer without the scientific context to reconcile the two.

The practical fix is straightforward but often skipped under deadline pressure: draft the lay summary as a genuinely separate document, not a simplified copy-paste of the scientific abstract, and have someone outside the lab — ideally someone with no scientific background — read it before submission and say back what they think the project does and why it matters.

The F&A Problem for Research Offices

Because most disease-charity awards cap indirect cost recovery well below an institution’s federally negotiated rate — often at a flat 0-15% of direct costs rather than the 50-70%+ a research-intensive university typically negotiates under 2 CFR 200 — research offices face a real, recurring decision: does the institution accept an award that recovers little or none of its actual overhead cost?

In practice, institutions handle this a few different ways, and a research office’s own policy on this should be settled and documented before a PI is deep into a disease-charity application, not discovered at proposal-routing time:

Blanket acceptance below a defined threshold. Many institutions maintain a standing list of pre-approved sponsors — typically nonprofit disease foundations and similar funders — for which a reduced or zero F&A rate is accepted automatically, without a case-by-case waiver request, precisely because this funding category is common enough to warrant a standing policy rather than repeated one-off exceptions.
Formal F&A waiver request, case by case. Institutions without a standing nonprofit-funder list typically require the PI or department to submit a waiver justification (often citing the funder’s published policy limiting indirect recovery) through the sponsored-programs office before the proposal can be routed.
Departmental or institutional cost-sharing to cover the gap. Some institutions treat the shortfall between the actual negotiated rate and the charity’s capped rate as a cost the department or central administration absorbs, effectively subsidizing the award because of its strategic or training value — common for early-career fellowship and career-development awards specifically, since these often fund a PI’s transition to independence rather than a mature research program.
Declining, in rare cases. An institution may decline to accept an award (or require the PI to seek supplementary internal funding) if the F&A shortfall on a large-budget award is judged too costly relative to the award’s size — uncommon for the modest award values typical of the charity mechanisms in this guide, but a real consideration for the rare larger, multi-year charity awards that approach R01-scale budgets.

Because disease-charity awards are common, recurring, and individually small, the standing-list approach is the one most large research offices converge on for efficiency — but the underlying policy decision (what F&A floor, if any, the institution will accept) has to be made deliberately rather than defaulting to whatever a given proposal happens to request.

Comparison: Major Disease-Focused Charity Research Funders

The table below covers the American Heart Association plus the other major US disease-focused charity funders commonly encountered by research offices. Award-value and F&A figures are shown only where independently confirmed against the funder’s own published policy this session; where a funder does not publish a single consistent figure across its award portfolio, that cell says so explicitly rather than estimating.

Charity	Disease focus	Award types (typical ladder)	Typical award value	F&A / indirect cap	Lay/patient review?
American Heart Association (AHA)	Cardiovascular disease, stroke	Predoctoral & postdoctoral fellowships; Career Development Award; innovation/project grants	CDA: up to $231,000 total over 3 years ($77,000/year)	CDA: 10% (institutional indirect included in the award total) — confirm other mechanisms directly	Not independently confirmed this session — check current review-panel composition on AHA’s site
American Cancer Society (ACS)	Cancer, all types	Postdoctoral fellowships; mentored/career-development-style scholar grants; institutional grants for new investigators	Not independently confirmed this session	Not independently confirmed this session	Not independently confirmed this session
Michael J. Fox Foundation (MJFF)	Parkinson’s disease	Target-validation, biomarker, and rapid, milestone-driven pilot/project grants (venture-philanthropy style, similar in structure to CFF below)	Not independently confirmed this session	Not independently confirmed this session	Not independently confirmed this session
Alzheimer’s Association	Alzheimer’s disease and related dementias	Predoctoral & postdoctoral fellowships; career-development-style grants; pilot/new-investigator research grants	Not independently confirmed this session	Not independently confirmed this session	Not independently confirmed this session
Susan G. Komen	Breast cancer	Postdoctoral fellowships; career-catalyst / career-development-style grants; leadership/program grants	Not independently confirmed this session	Not independently confirmed this session	Yes — Advocates in Science program trains breast cancer survivors/previvors as grant reviewers
Cystic Fibrosis Foundation (CFF)	Cystic fibrosis	Pilot & Feasibility Awards; Clinical Pilot & Feasibility Awards; separately, a venture-philanthropy arm (CFFT) that invests in therapeutics rather than making unconditional research grants — see the dedicated CFF guide	Pilot & Feasibility Award: up to $50,000/year, up to 2 years	Pilot & Feasibility Award: 12% capped indirect	Not independently confirmed this session
JDRF (now Breakthrough T1D)	Type 1 diabetes	Postdoctoral fellowships; career-development-style awards; innovative/pilot research grants	Not independently confirmed this session	Not independently confirmed this session	Not independently confirmed this session
Muscular Dystrophy Association (MDA)	Muscular dystrophy and related neuromuscular diseases	Development grants (early-career); research grants (established investigators)	Not independently confirmed this session	Not independently confirmed this session	Not independently confirmed this session
American Diabetes Association (ADA)	Diabetes (type 1 and type 2)	Postdoctoral fellowships; career-development-style awards; innovation/basic-science research grants	Not independently confirmed this session	Not independently confirmed this session	Not independently confirmed this session
Leukemia & Lymphoma Society (LLS)	Blood cancers (leukemia, lymphoma, myeloma)	Postdoctoral fellowships; career-development-style awards; translational/pilot research grants	Not independently confirmed this session	Not independently confirmed this session	Not independently confirmed this session

The gaps in this table are deliberate, not an oversight: every “not independently confirmed” cell reflects a real limitation on what could be freshly verified against each funder’s own published policy in this session (several of these organizations’ funding pages are JavaScript-rendered and did not return readable policy text to automated retrieval), rather than a figure carried over from memory. Research offices should treat every cell in this table as a starting point for a direct check against the named funder’s current published grant policy before it is used in an actual proposal budget — award terms, and especially F&A caps, are revised by these funders without a fixed public schedule.

Frequently Asked Questions

How is disease-charity research funding different from NIH funding?

The core differences are size, duration, and cost structure: charity awards are typically smaller and shorter than comparable NIH mechanisms, cap indirect/F&A cost recovery at a flat, low rate (often 0-15%) rather than an institution’s federally negotiated rate, usually require a plain-language lay summary as a mandatory component, and often build patient or advocate reviewers into the review process alongside scientific peer reviewers.

Do disease charities use the same F/K/R grant-mechanism names as NIH?

No. Charities use their own naming conventions — “fellowship,” “career development award,” “pilot grant,” “innovation grant” — but the underlying structure (a predoctoral rung, a postdoctoral rung, a mentored-career rung, and a project/pilot rung) maps loosely onto the NIH F31/F32/K/R progression, which is why that mapping is useful for a researcher translating between the two systems.

Will my institution accept a disease-charity award that recovers little or no indirect cost?

Most research-intensive institutions do, usually through a standing list of pre-approved nonprofit/disease-foundation sponsors for which a reduced F&A rate is accepted without a case-by-case waiver, because this funding category is common enough to justify a standing policy. Institutions without such a list typically require a formal F&A waiver request through the sponsored-programs office. Confirm your own institution’s specific policy before submitting — this varies by institution and is not something a funder’s own policy can answer for you.

What is patient-advocate or lay review, and why does it matter?

It is the practice, used by a number of disease-focused charities, of including non-scientist patients, survivors, or caregivers in the grant review process — either scoring proposals directly or providing a relevance-to-patients assessment that factors into the funding decision. Proposals fail it most often because the lay summary is written like a scientific abstract rather than genuinely plain language, or because the patient-relevance case is asserted rather than concretely shown.

Can a junior investigator build a full research program on disease-charity funding alone?

In practice, most junior investigators use disease-charity awards to stack a funding portfolio — a postdoctoral fellowship, then a career-development award, then one or more pilot/innovation grants — because individual charity mechanisms are rarely as large as an R01. Charity funding is frequently the bridge that generates the preliminary data needed to compete for larger federal awards later, rather than a full substitute for them.